Hint mode is switched on Switch off

Arcutis Biotherapeutics, ordinary share
ARQT, US03969K1088

Add a stock to WL
Choose all Reset all
Arcutis Biotherapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Arcutis Biotherapeutics Inc operates as a biopharmaceutical company. The Company focuses on developing treatments for unmet needs in immune-mediated diseases and conditions. Arcutis Biotherapeutics serves medical sector in the United States.
  • Issuer
  • Full borrower / issuer name
    Arcutis Biotherapeutics Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARQT
  • Placement
    31.01.2020
  • Lock up period
    180
  • Number of papers
    9,375,000
  • Volume of raised funds
    159.38 mln USD
  • Placement share
    25.6%
  • Final placement price
    17 USD
  • Price change since placement date
    -100%
  • By capitalization
    622.66 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARQT
  • Placement
    05.10.2020
  • Lock up period
    180
  • Number of papers
    4,000,000
  • Volume of raised funds
    100 mln USD
  • Placement share
    9.28%
  • Final placement price
    25 USD
  • Price change since placement date
    2.8%
  • By capitalization
    1,077.25 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARQT
  • Placement
    04.02.2021
  • Lock up period
    180
  • Number of papers
    5,500,000
  • Volume of raised funds
    192.5 mln USD
  • Placement share
    11.29%
  • Final placement price
    35 USD
  • Price change since placement date
    -26.57%
  • By capitalization
    1,704.46 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARQT
  • Placement
    01.03.2024
  • Lock up period
    180
  • Number of papers
    112,576,817
  • Volume of raised funds
    150 mln USD
  • Placement share
    14.03%
  • Final placement price
    9.5 USD
  • Price change since placement date
    170.53%
  • By capitalization
    1,069.48 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

26/02/2026 Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Surpasses Earnings Expectations and Shows Strong Revenue Growth
03/12/2025 Arcutis Biotherapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd Disclosure, Financial Statements And Exhibits
30/10/2025 Arcutis Biotherapeutics' Capital Efficiency Challenges
12/06/2025 Arcutis Biotherapeutics: Financial Statements And Exhibits
10/04/2025 Arcutis Biotherapeutics: , Including Exhibit 99.1, Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Otherwise Subject To The Liabilities Of That Section, And Shall Not Be Deemed To Be Incorporated By Reference Into Any Filing Made By The Company Under The Securities Exchange Act Of 1934, As Amended, Or The Securities Exchange Act Of 1933, As Amended, Regardless Of Any General Incorporation Language In Any Such Filings, Except As Shall Be Expressly Set Forth By Specific Reference In Such A Filing, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.